Member Info for EmeraldCarrots

Of it, with a £50 million share buy back and seemingly fantastic results one wonders why the sp has not (yet?) rocketed North? Also why has it fallen from the 1700p back in Sept 2024 to the 1252 it is now. Seems odd! Up 3.65% at the moment. See how it goes.......

On the MT-RNR1 ID kit. An update on this:-

https://www.lse.co.uk/rns/GDR/breakthrough-device-designation-from-the-us-fda-2zclfstav7guqaq.html

Also, I think the market will be surprised by the international sales of the MT-RNR1 ID kit. Parents do not want to risk their baby being rendered deaf by a hospital administering an antibiotic!

All IMHO.

Presume by your continual negative postings you have certainly not got a long position. Have you managed to short GDR then? If you don't reply I think we can assume you have.

Contract will see the sp here ROCKET North. An Astrazeneca contract would put the sp off World! A matter of time.... One Astrazeneca drug trial contract would inevitable lead to more.

All IMHO.

Sell the MT-RNR1 ID machine, that is used to test babies to see if they might be rendered stone deaf by a aminoglycoside antibiotic then I will be shocked. You could not hope for a better sales pitch to a neonatal hospital. So "use the machine and be confident of no bad reaction and no parents suing you", or "don't use the machine and keep your fingers crossed"!. LOL! How ridiculous.

All IMHO.

Better sales pitch than using the Geredrive MT-RNR1 ID machine might stop your baby being rendered stone deaf!!

There are only so many neonatal hospitals in the UK. However, this machine will be Genedrive's most lucrative product. This is why FDA approval in the USA is key. Having said that and sales team with any sense should be selling these by the shed load as parents in ANY country in the World won't want to risk their baby being rendered deaf by being given an antibiotic! News on the FDA application PLEASE!!!!!!!

ALl IMHO.

Staff must have capitalised on this machine's ability to identify babies that might be rendered deaf by aminoglycoside induced hearing loss. It is a disgrace that this commonly used neonatal antibiotic sometimes makes babies deaf when it can be avoided by testing them with the MT-RNR1 ID kit. Sales figures in the half year report, due this week surely will reflect this. It is difficult to think of a better sales pitch. Salespersons dream in fact.

All IMHO.

I can't see how Angle's "dual analysis" won't be adopted for drug trials going forward. The Illumina assay panel **for Lung cancer** that fits with Angle's Parsortix system has been available for several weeks now. Obviously, Illumina are World Wide. Although Parsortix is not mentioned yet on Illumina's web page I'm sure once a potential client makes enquiries they will be told what systems are available. Parsortix is the "Gold standard" for the dual analysis that Angle pioneered. In fact, I think it is the only one currently available for the dual analysis. I'm sure they are getting enquiries through in increasing numbers.

All IMHO.

With Angle Plc soon. Astrazeneca paid Angle to develop two assays for use in cancer drug trials. They are done and ready for use as the RNS says. So, the next RNS will probably be Astra contracting Angle to use one or both assays in one (or more) of their cancer drug trials. If not, why on Earth would they have paid for them to be made? This is the Elephant in the room that the market has not noticed for now....... How daft.

https://www.lse.co.uk/rns/AGL/results-of-eisai-phase-2-pilot-study-6iqrzshixk4v0my.html

All IMHO.

If the sp is over 25p. It seems unlikely they are going to do another placing any time soon as this would dilute the share price. Astrazeneca paid Angle to develop two assays for use in cancer drug trials. They are done and ready for use as the RNS says. So, the next RNS will probably be Astra contracting Angle to use one or both assays in one (or more) of their cancer drug trials. If not, why on Earth would they have paid for them to be made? This is the Elephant in the room that the market has not noticed for now....... How daft.

All IMHO.

Soon. The new director share options don't make money until the sp is 25p plus.

Angle now have 3 new assays to offer for use in the lucrative cancer drug trial markets all over the World........ 2 paid for by Astrazeneca that Astra surely will now want to use in future trials. Why would they pay for them otherwise FFS!

Confirmation they are ready to use:-

https://www.lse.co.uk/rns/AGL/results-of-eisai-phase-2-pilot-study-6iqrzshixk4v0my.html

The original RNS's from last year saying Astra want the assays developed for drug trials!

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

All IMHO.

By any stretch it is fantastically good news, yet the sp has slightly DROPPED because of I think a massive sell overhang that is now being consumed. Once overcome the sp should rocket. 12p plus today would not surprise me at all. Astrazeneca paid Angle to produce the 2 assays so they can USE THEM IN CANCER TRIALS FFS!! The market seems not to understand this?! Also, as Angle own the rights they can offer using them for any other cancer drug trial in the World.

Confirmation they are ready to use:-

https://www.lse.co.uk/rns/AGL/results-of-eisai-phase-2-pilot-study-6iqrzshixk4v0my.html

The original RNS's from last year saying Astra want the assays developed for drug trials!

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

Completely BONKERS sp or what. I have bought some more @ 9.3p

May add more if the sp starts to motor as I expect it will later.

All IMHO.

Contract Angle to produce these two assays if they do not intend to use them?????????????????????? HAS THE MARKET LOST THE PLOT! THE SP is down!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Confirmation they are ready to use:-

https://www.lse.co.uk/rns/AGL/results-of-eisai-phase-2-pilot-study-6iqrzshixk4v0my.html

The original RNS's from last year saying Astra want the assays developed for drug trials!

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

WHY ELSE WOULD THEY HAVE CONTRACTED ANGLE?

Must be some sort of share overhang from some massive share sell which may have been in error if you ask me.

Maybe a limit to sell got triggered??

All IMHO.

There are loads of Breast cancer HER2 cancer drug trials being carried out. I mean hundreds all over the World, maybe even thousands. The Eisai Inc contract has now confirmed breast cancer HER2 status changes over time. This information is vital in giving the correct treatment. If the HER2 status of the Breast cancer measured from the original solid tumour changes from positive to being negative just before treatment starts the treatment will not work. I'd say that is a tad important. Waiting for the first contract to roll in for this now. I see contract numbers in the teens in 6 months and 20 plus in 12 months.

All IMHO.

B_Positive

"The tech works, next stop Astrazeneca deal".

======================

Hello,

Exactly. There was no guarrantee Angle could produce these assays. They are state of the art tech. They are done and they work. Now not only Astrazeneca but any other Company can employ Angle to use these assays during cancer drug trials. It is fantastic news!! As the RNS says Angle are working for Astra using these assays NOW.

All IMHO.

Massive share SALE overhang? Only explanation I can think of for the sp drop! Maybe some players limit to sell was hit! What a mistakea to makea! Once the market has eaten it's way through these the so will ROCKECT. Wait for it...............

All IMHO.

Don't forget Angle own the rights to the tests! Angle can now offer the AR and DDR testing to ANY CLIENT IN THE WORLD. Same for the Eisai Inc. HER2 test. This news is transformational for Angle Plc. Their salespeople must have a permanent smile on their face. What a position to be in!

It's pretty obvious the Directors are absolutely sure these three successful contract executions (2 x Astrazeneca and 1 x Eisai Inc.) will lead to multi-million £ contracts in short order. Market awaits.............

Https://www.lse.co.uk/rns/AGL/results-of-eisai-phase-2-pilot-study-6iqrzshixk4v0my.html

All IMHO.

Https://www.lse.co.uk/rns/AGL/results-of-eisai-phase-2-pilot-study-6iqrzshixk4v0my.html

Update on AstraZeneca assay development projects

"Both the developed assays (AR and DDR) have been approved for use by AstraZeneca and we are currently using the assays to test blood samples from patients. These developments put ANGLE in the position to be able to execute large scale clinical trials for AstraZeneca. In addition, ANGLE is working to progress discussions in other areas where we believe AstraZeneca could benefit from adopting CTC analysis.".

---------------------------------------------

Results of Eisai Phase 2 pilot study

"In addition, BlissBio, have confirmed their intention to progress BB-1701 themselves. Accordingly, ANGLE is now seeking to engage with BlissBio in order to work with them on the next stage of development of BB-1701 although at this stage we have no specifics on this.".

=====================================

The sp should be North of 30p by now. Market asleep still.............. THIS CANNOT LAST. Angle are working for Astrazeneca processing blood samples now, as the RNS says.

The potential £ here is in the tens of millions for just 1 drug trial contract!! Let alone several or more. Plus what do they get for the on-going tests for Astra?

All IMHO.